11:30 am – 12:30 pm Saturday, September 15

Impact of Donor Selection in Hematopoietic Stem Cell Transplant Outcomes (224)

1CNE Hematopoietic stem cell transplant (HSCT) is an important therapeutic option for children with malignant and nonmalignant disease. Over the past 50 years, there has been an increasing number of indications for HSCT. Human leukocyte antigen (HLA) matched related donors offer the best outcome and frequently donors are siblings that are children. Haploidentical and unrelated donors have expanded the pool of donors. Improved HLA typing and posttransplant supportive care has improved the outcome of HSCT from alternative donors. The American Academy of Pediatrics published a statement regarding pediatric patients undergoing HSCT. The policy recommended new standards that had significant impact on both pediatric stem cell transplant physicians and parents. Choosing the appropriate donor depends on the patient and donor’s degree of HLA matching, sex, parity, blood type, CMV status, HLA directed antibodies, and the health of the donor.


Bone Marrow Transplant for Hematology Patients: Caring for the Patient from Diagnosis to Long Term Follow Up (006)

3.25CNE  There are an increasing numbers of patients with hematologic transplant as a curative therapy, for previously life-threatening and life-limiting diagnosis. There continues to be advancement in this area on options available to patients to allow for overall increased survival and improved outcomes. With these new advancements, there presents a challenge to manage these patients effectively pre- and post-transplant to improve outcomes and survival. This presentation will provide an overview of transplant for hematology patients, which will include indications for transplant, criteria to qualify for transplant, pre- and post-transplant considerations (infectious, social, etc.), an overview of medications specific to hematologic conditions prior to transplant; types of transplants used, hematologic specific complications pre- and post-transplant, long-term follow up considerations in the post-transplant patient, and new and emerging therapies in the hematology patient and transplant.

Subscribe to this RSS feed